
1 NEXAVAR®

- 2 (sorafenib)
- 3 tablets 200 mg

4 **DESCRIPTION**

- 5 NEXAVAR, a multikinase inhibitor targeting several serine/threonine and receptor tyrosine 6 kinases, is the tosylate salt of sorafenib.
- 7 Sorafenib tosylate has the chemical name 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]
- 8 ureido}phenoxy)- N^2 -methylpyridine-2-carboxamide 4-methylbenzenesulfonate and its
- 9 structural formula is:



10

- 11 Sorafenib tosylate is a white to yellowish or brownish solid with a molecular formula of
- 12 $C_{21}H_{16}ClF_3N_4O_3 \ge C_7H_8O_3S$ and a molecular weight of 637.0 g/mole. Sorafenib tosylate is
- 13 practically insoluble in aqueous media, slightly soluble in ethanol and soluble in PEG 400.

Each red, round NEXAVAR film-coated tablet contains sorafenib tosylate (274 mg)
equivalent to 200 mg of sorafenib and the following inactive ingredients:

16 croscarmellose sodium, microcrystalline cellulose, hypromellose, sodium lauryl sulphate,

17 magnesium stearate, polyethylene glycol, titanium dioxide and ferric oxide red.

18 CLINICAL PHARMACOLOGY

19 Mechanism of Action

20 Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib

21 inhibited tumor growth of the murine renal cell carcinoma, RENCA, and several other human

22 tumor xenografts in athymic mice. A reduction in tumor angiogenesis was seen in some

23 tumor xenograft models. Sorafenib was shown to interact with multiple intracellular (CRAF,

- 24 BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, VEGFR- 2, VEGFR- 3, and
- 25 PDGFR- β). Several of these kinases are thought to be involved in angiogenesis.

26 **Pharmacokinetics**

After administration of NEXAVAR tablets, the mean relative bioavailability is 38-49% when compared to an oral solution. The mean elimination half-life of sorafenib is approximately 25-48 hours. Multiple dosing of NEXAVAR for 7 days resulted in a 2.5- to 7-fold accumulation compared to single dose administration. Steady-state plasma sorafenib concentrations are achieved within 7 days, with a peak-to-trough ratio of mean concentrations of less than 2.

33 Absorption and Distribution

Following oral administration, sorafenib reaches peak plasma levels in approximately 3 hours. When given with a moderate-fat meal, bioavailability was similar to that in the fasted state. With a high-fat meal, sorafenib bioavailability was reduced by 29% compared to administration in the fasted state. It is recommended that NEXAVAR be administered without food (at least 1 hour before or 2 hours after eating) (see **DOSAGE AND ADMINISTRATION** section).

- Mean C_{max} and AUC increased less than proportionally beyond doses of 400 mg administered
 orally twice daily.
- 42 *In vitro* binding of sorafenib to human plasma proteins is 99.5%.

43 Metabolism and Elimination

- 44 Sorafenib is metabolized primarily in the liver, undergoing oxidative metabolism, mediated 45 by CYP3A4, as well as glucuronidation mediated by UGT1A9.
- 46 Sorafenib accounts for approximately 70-85% of the circulating analytes in plasma at steady-
- 47 state. Eight metabolites of sorafenib have been identified, of which five have been detected in
- 48 plasma. The main circulating metabolite of sorafenib in plasma, the pyridine N-oxide, shows
- 49 *in vitro* potency similar to that of sorafenib. This metabolite comprises approximately 9-16%
- 50 of circulating analytes at steady-state.
- 51 Following oral administration of a 100 mg dose of a solution formulation of sorafenib, 96%
- 52 of the dose was recovered within 14 days, with 77% of the dose excreted in feces, and 19% of
- 53 the dose excreted in urine as glucuronidated metabolites. Unchanged sorafenib, accounting
- 54 for 51% of the dose, was found in feces but not in urine.

55 Special Populations

56 Analyses of demographic data suggest that no dose adjustments are necessary for age or

57 gender.

58 **Race**

- 59 Limited pharmacokinetic data on sorafenib 400 mg twice daily in a study in Japanese patients
- 60 (n=6) showed a 45% lower systemic exposure (mean steady-state AUC) as compared to
- 61 pooled Phase 1 pharmacokinetic data in Caucasian patients (n=25). The clinical significance
- 62 of this finding is not known (see **PRECAUTIONS General** *Race*).

64 **Pediatric**

65 There are no pharmacokinetic data in pediatric patients.

66 Hepatic Impairment

67 Sorafenib is cleared primarily by the liver.

In patients with mild (Child-Pugh A, n=14) or moderate (Child-Pugh B, n=8) hepatic
impairment, exposure values were within the range observed in patients without hepatic
impairment. The pharmacokinetics of sorafenib have not been studied in patients with severe
(Child-Pugh C) hepatic impairment (See **PRECAUTIONS – Patients with Hepatic Impairment** section).

73 **Renal Impairment**

In a study of drug disposition after a single oral dose of radiolabeled sorafenib to healthy
 subjects, 19% of the administered dose of sorafenib was excreted in urine.

In four Phase 1 clinical trials, sorafenib was evaluated in patients with normal renal function
(n=71) and in patients with mild renal impairment (CrCl >50–80 mL/min, n=24) or moderate
renal impairment (CrCl 30–50 mL/min, n=4). No relationship was observed between renal
function and steady-state sorafenib AUC at doses of 400 mg twice daily. The
pharmacokinetics of sorafenib have not been studied in patients with severe renal impairment
(CrCl <30 ml/min) or in patients undergoing dialysis (see PRECAUTIONS – Patients with
Renal Impairment section).

83 Drug-Drug Interactions

84 CYP3A4 inhibitors: In vitro data indicate that sorafenib is metabolized by CYP3A4 and 85 UGT1A9 pathways. Ketoconazole (400 mg), a potent inhibitor of CYP3A4, administered 86 once daily for 7 days did not alter the mean AUC of a single oral 50 mg dose of sorafenib in 87 healthy volunteers. Therefore, sorafenib metabolism is unlikely to be altered by CYP3A4 88 inhibitors.

89 *CYP isoform-selective substrates:* Studies with human liver microsomes demonstrated that 90 sorafenib is a competitive inhibitor of CYP2C19, CYP2D6, and CYP3A4 as indicated by K_i 91 values of 17 μ M, 22 μ M, and 29 μ M, respectively. Administration of NEXAVAR 400 mg 92 twice daily for 28 days did not alter the exposure of concomitantly administered midazolam 93 (CYP3A4 substrate), dextromethorphan (CYP2D6 substrate), and omeprazole (CYP2C19 94 substrate). This indicates that sorafenib is unlikely to alter the metabolism of substrates of 95 these enzymes *in vivo*.

96 *CYP2C9 substrates:* Studies with human liver microsomes demonstrated that sorafenib is a 97 competitive inhibitor of CYP2C9 with a K_i value of 7-8 μ M. The possible effect of sorafenib 98 on the metabolism of the CYP2C9 substrate warfarin was assessed indirectly by measuring 99 PT-INR. The mean changes from baseline in PT-INR were not higher in NEXAVAR

63

patients compared to placebo patients, suggesting that sorafenib did not inhibit warfarin
 metabolism *in vivo* (see **PRECAUTIONS** – *Warfarin Co-administration* section).

CYP3A4 inducers: There is no clinical information on the effect of CYP3A4 inducers on the
 pharmacokinetics of sorafenib. Substances that are inducers of CYP3A4 activity (e.g.
 rifampin, St. John's wort, phenytoin, carbamazepine, phenobarbital, and dexamethasone) are
 expected to increase metabolism of sorafenib and thus decrease sorafenib concentrations.

106 *Combination with other antineoplastic agents:* In clinical studies, NEXAVAR has been 107 administered with a variety of other antineoplastic agents at their commonly used dosing 108 regimens, including gemcitabine, oxaliplatin, doxorubicin, and irinotecan. Sorafenib had no 109 effect on the pharmacokinetics of gemcitabine or oxaliplatin. Concomitant treatment with 110 NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. When administered with 111 irinotecan, whose active metabolite SN-38 is further metabolized by the UGT1A1 pathway, 112 there was a 67-120% increase in the AUC of SN-38 and a 26-42% increase in the AUC of

113 irinotecan. The clinical significance of these findings is unknown (see **PRECAUTIONS** –

- 114 **Drug Interactions** sections).
- 115 In vitro studies

116 In vitro studies of enzyme inhibition: Sorafenib inhibits CYP2B6 and CYP2C8 in vitro with

- 117 K_i values of 6 and 1-2 μ M, respectively. Systemic exposure to substrates of CYP2B6 and
- 118 CYP2C8 is expected to increase when co-administered with NEXAVAR.
- 119 Sorafenib inhibits glucuronidation by the UGT1A1 (K_i value: 1 µM) and UGT1A9 pathways
- 120 (K_i value: $2 \mu M$). Systemic exposure to substrates of UGT1A1 and UGT1A9 may increase
- 121 when co-administered with NEXAVAR.

122 In vitro studies of CYP enzyme induction: CYP1A2 and CYP3A4 activities were not altered

123 after treatment of cultured human hepatocytes with sorafenib, indicating that sorafenib is 124 unlikely to be an inducer of CYP1A2 or CYP3A4.

125 CLINICAL STUDIES

The safety and efficacy of NEXAVAR in the treatment of advanced renal cell carcinoma(RCC) were studied in the following 2 randomized controlled clinical trials.

Study 1 was a Phase 3, international, multicenter, randomized, double blind, placebocontrolled trial in patients with advanced renal cell carcinoma who had received one prior systemic therapy. Primary study endpoints included overall survival and progression-free survival (PFS). Tumor response rate was a secondary endpoint. The PFS analysis included 769 patients stratified by MSKCC (Memorial Sloan Kettering Cancer Center) prognostic risk category¹ (low or intermediate) and country and randomized to NEXAVAR 400 mg twice

134 daily (N=384) or to placebo (N=385).

Table 1 summarizes the demographic and disease characteristics of the study population analyzed. Baseline demographics and disease characteristics were well balanced for both


- 137 treatment groups. The median time from initial diagnosis of RCC to randomization was 1.6
- 138 and 1.9 years for the NEXAVAR and placebo groups, respectively.

Characteristics	NEXAVA	R N=384	Placebo	N=385	
Characteristics	Ν	(%)	n	(%)	
Gender					
Male	267	(70)	287	(75)	
Female	116	(30)	98	(25)	
Race					
White	276	(72)	278	(73)	
Black/Asian/	11	(3)	10	(2)	
Hispanic/Other					
Not reported ^a	97	(25)	97	(25)	
Age group					
< 65 years	255	(67)	280	(73)	
≥ 65 years	127	(33)	103	(27)	
ECOG performan	ce status at	baseline			
0	184	(48)	180	(47)	
1	191	(50)	201	(52)	
2	6	(2)	1	(<1)	
Not reported	3	(<1)	3	(<1)	
MSKCC prognost	ic risk categ	jory ¹			
Low	200	(52)	194	(50)	
Intermediate	184	(48)	191	(50)	
Prior IL-2 and/or i	nterferon				
Yes	319	(83)	313	(81)	
No	65	(17)	72	(19)	

139
 Table 1: Demographic and Disease Characteristics - Study 1

a. Race was not collected from the 186 patients enrolled in France due to local regulations. In 8 other patients, race was not available at the time of analysis.

Progression-free survival, defined as the time from randomization to progression or death from any cause, whichever occurred earlier, was evaluated by blinded independent radiological review using RECIST criteria. Figure 1 depicts Kaplan-Meier curves for PFS. The PFS analysis was based on a two-sided Log-Rank test stratified by MSKCC prognostic risk category¹ and country.



145 Figure 1: Kaplan-Meier Curves for Progression-free Survival – Study 1

146

147NOTE: HR is from Cox regression model with the following covariates: MSKCC prognostic risk category1 and country.148P-value is from two-sided Log-Rank test stratified by MSKCC prognostic risk category1 and country.

The median PFS for patients randomized to NEXAVAR was 167 days compared to 84 days for patients randomized to placebo. The estimated hazard ratio (risk of progression with NEXAVAR compared to placebo) was 0.44 (95% CI: 0.35, 0.55).

152 A series of patient subsets were examined in exploratory univariate analyses of PFS. The

subsets included age above or below 65 years, ECOG PS 0 or 1, MSKCC prognostic risk

154 category¹, whether the prior therapy was for progressive metastatic disease or for an earlier

155 disease setting, and time from diagnosis of less than or greater than 1.5 years. The effect of

156 NEXAVAR on PFS was consistent across these subsets, including patients with no prior IL-2

157 or interferon therapy (n=137; 65 patients receiving NEXAVAR and 72 placebo), for whom

158 the median PFS was 172 days on NEXAVAR compared to 85 days on placebo.

Tumor response was determined by independent radiological review according to RECIST criteria. Overall, of 672 patients who were evaluable for response, 7 (2%) NEXAVAR patients and 0 (0%) placebo patients had a confirmed partial response. Thus the gain in PFS

162 in NEXAVAR-treated patients primarily reflects the stable disease population.

- 163 At the time of a planned interim survival analysis, based on 220 deaths, overall survival was
- longer for NEXAVAR than placebo with a hazard ratio (NEXAVAR over placebo) of 0.72.
- 165 This analysis did not meet the prespecified criteria for statistical significance. Additional
- 166 analyses are planned as the survival data mature.

167 Study 2 was a Phase 2 randomized discontinuation trial in patients with metastatic malignancies, including RCC. The primary endpoint was the percentage of randomized 168 169 patients remaining progression-free at 24 weeks. All patients received NEXAVAR for the 170 first 12 weeks. Radiologic assessment was repeated at week 12. Patients with <25% change 171 in bi-dimensional tumor measurements from baseline were randomized to NEXAVAR or 172 placebo for a further 12 weeks. Patients who were randomized to placebo were permitted to 173 cross over to open-label NEXAVAR upon progression. Patients with tumor shrinkage $\geq 25\%$ 174 continued NEXAVAR, whereas patients with tumor growth \geq 25% discontinued treatment.

175 Two hundred and two patients with advanced RCC were enrolled into Study 2, including 176 patients who had received no prior therapy and patients with tumor histology other than clear 177 cell carcinoma. After the initial 12 weeks of NEXAVAR therapy, 79 RCC patients continued 178 on open-label NEXAVAR, and 65 patients were randomized to NEXAVAR or placebo. 179 After an additional 12 weeks, at week 24, for the 65 randomized patients, the progression-free 180 rate was significantly higher in patients randomized to NEXAVAR (16/32, 50%) than in 181 patients randomized to placebo (6/33, 18%) (p=0.0077). Progression-free survival was 182 significantly longer in the NEXAVAR group (163 days) than in the placebo group (41 days) 183 (p=0.0001, HR=0.29).

184 INDICATIONS AND USAGE

185 NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma.

186 CONTRAINDICATIONS

187 NEXAVAR is contraindicated in patients with known severe hypersensitivity to sorafenib or188 any other component of NEXAVAR.

189 WARNINGS

190 Pregnancy Category D

191 In rats and rabbits, sorafenib has been shown to be teratogenic and to induce embryo-fetal 192 toxicity (including increased post-implantation loss, resorptions, skeletal retardations, and 193 retarded fetal weight). The effects occurred at doses considerably below the recommended human dose of 400 mg twice daily (approximately 500 mg/m²/day on a body surface area 194 195 basis). Adverse intrauterine development effects were seen at doses $\geq 1.2 \text{ mg/m}^2/\text{day}$ in rats 196 and 3.6 mg/m²/day in rabbits (approximately 0.008 times the AUC seen in cancer patients at 197 the recommended human dose). A NOAEL (no observed adverse effect level) was not 198 defined for either species, since lower doses were not tested.

199 Based on the proposed mechanism of multikinase inhibition and multiple adverse effects seen

- 200 in animals at exposure levels significantly below the clinical dose, sorafenib should be
- assumed to cause fetal harm when administered to a pregnant woman. If this drug is used
- 202 during pregnancy, or if the patient becomes pregnant while taking this drug, the patient
- should be apprised of the potential hazard to the fetus (see **PRECAUTIONS Information**
- 204 **for Patients** section).

There are no adequate and well-controlled studies in pregnant women using NEXAVAR. Women of childbearing potential should be advised to avoid becoming pregnant while on NEXAVAR. NEXAVAR should be used during pregnancy only if the potential benefits justify the potential risks to the fetus (see **PRECAUTIONS – Information for Patients** section).

210 **PRECAUTIONS**

211 General

212 Dermatologic Toxicities: Hand-foot skin reaction and rash represent the most common adverse events attributed to NEXAVAR. Analysis of cumulative event rates from Study 1 213 214 suggest that rash and hand-foot skin reaction are usually CTCAE Grade 1 and 2 and generally 215 appear during the first six weeks of treatment with NEXAVAR. Management of 216 dermatologic toxicities may include topical therapies for symptomatic relief, temporary 217 treatment interruption and/or dose modification of NEXAVAR, or in severe or persistent 218 cases, permanent discontinuation of NEXAVAR. Permanent discontinuation of therapy due 219 to hand-foot skin reaction occurred in 3 of 451 NEXAVAR patients.

220 Hypertension: In Study 1, treatment-emergent hypertension was reported in approximately 221 16.9% of NEXAVAR-treated patients and 1.8% of patients in the placebo group. 222 Hypertension was usually mild to moderate, occurred early in the course of treatment, and 223 was managed with standard antihypertensive therapy. Blood pressure should be monitored 224 weekly during the first 6 weeks of NEXAVAR therapy and thereafter monitored and treated, 225 if required, in accordance with standard medical practice. In cases of severe or persistent 226 hypertension, despite institution of antihypertensive therapy, temporary or permanent 227 discontinuation of NEXAVAR should be considered. Permanent discontinuation due to 228 hypertension occurred in 1 of 451 NEXAVAR patients.

- 229 *Hemorrhage:* An increased risk of bleeding may occur following NEXAVAR 230 administration. In Study 1, bleeding regardless of causality was reported in 15.3% of patients 231 in the NEXAVAR group and 8.2% of patients in the placebo group. The incidence of 232 CTCAE Grade 3 and 4 bleeding events was 2% and 0%, respectively, in NEXAVAR 233 patients, and 1.3% and 0.2%, respectively, in placebo patients. There was one fatal 234 hemorrhage in each treatment group in Study 1. If any bleeding event necessitates medical 235 intervention, permanent discontinuation of NEXAVAR should be considered.
- 236 Cardiac Ischemia and/or Infarction: In Study 1, the incidence of treatment-emergent cardiac
- ischemia/infarction events was higher in the NEXAVAR group (2.9%) compared with the
- 238 placebo group (0.4%). Patients with unstable coronary artery disease or recent myocardial

- infarction were excluded from this study. Temporary or permanent discontinuation of
 NEXAVAR should be considered in patients who develop cardiac ischemia and/or infarction.
- 241 Race: Limited pharmacokinetic data on sorafenib 400 mg twice daily in a study in Japanese
- 242 patients (n=6) showed a 45% lower systemic exposure (mean steady-state AUC) as compared
- 243 to pooled Phase 1 pharmacokinetic data in Caucasian patients (n=25). The clinical $\frac{244}{1000}$
- 244 significance of this finding is not known.
- Warfarin Co-administration: Infrequent bleeding events or elevations in the International
 Normalized Ratio (INR) have been reported in some patients taking warfarin while on
 NEXAVAR therapy. Patients taking concomitant warfarin should be monitored regularly for
 changes in prothrombin time, INR or clinical bleeding episodes.
- Wound Healing Complications: No formal studies of the effect of NEXAVAR on wound healing have been conducted. Temporary interruption of NEXAVAR therapy is recommended in patients undergoing major surgical procedures. There is limited clinical experience regarding the timing of reinitiation of NEXAVAR therapy following major surgical intervention. Therefore, the decision to resume NEXAVAR therapy following a major surgical intervention should be based on clinical judgment of adequate wound healing.

255 **Drug Interactions**

256 Caution is recommended when administering NEXAVAR with compounds that are

- 257 metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan) (see
 258 CLINICAL PHARMACOLOGY Drug-Drug Interactions section).
- 259 Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of 260 doxorubicin. Caution is recommended when administering doxorubicin with NEXAVAR.
- 261 Sorafenib inhibits CYP2B6 and CYP2C8 *in vitro* with K_i values of 6 and 1-2 μ M, 262 respectively. Systemic exposure to substrates of CYP2B6 and CYP2C8 is expected to 263 increase when co-administered with NEXAVAR. Caution is recommended when 264 administering substrates of CYP2B6 and CYP2C8 with NEXAVAR.

265 **Patients with Hepatic Impairment**

In vitro and *in vivo* data indicate that sorafenib is primarily metabolized by the liver.
Systemic exposure and safety data were comparable in patients with Child-Pugh A and B
hepatic impairment. NEXAVAR has not been studied in patients with Child-Pugh C hepatic
impairment. No dose adjustment is necessary when administering NEXAVAR to patients
with Child-Pugh A and B hepatic impairment (see CLINICAL PHARMACOLOGY –
Hepatic Impairment section).

272 **Patients with Renal Impairment**

- 273 NEXAVAR has not been studied in patients with severe renal impairment
- 274 (CrCl <30 mL/min) or in patients undergoing dialysis.

275 Carcinogenesis, Mutagenesis, Impairment of Fertility

276 Carcinogenicity studies have not been performed with sorafenib.

Sorafenib was clastogenic when tested in an *in vitro* mammalian cell assay (Chinese Hamster Ovary) in the presence of metabolic activation. Sorafenib was not mutagenic in the *in vitro* Ames bacterial cell assay or clastogenic in an *in vivo* mouse micronucleus assay. One intermediate in the manufacturing process, which is also present in the final drug substance (<0.15%), was positive for mutagenesis in an *in vitro* bacterial cell assay (Ames test) when tested independently.

283 No specific studies with sorafenib have been conducted in animals to evaluate the effect on 284 fertility. However, results from the repeat-dose toxicity studies suggest there is a potential for 285 sorafenib to impair reproductive performance and fertility. Multiple adverse effects were 286 observed in male and female reproductive organs, with the rat being more susceptible than 287 mice or dogs. Typical changes in rats consisted of testicular atrophy or degeneration, 288 degeneration of epididymis, prostate, and seminal vesicles, central necrosis of the corpora 289 lutea and arrested follicular development. Sorafenib-related effects on the reproductive 290 organs of rats were manifested at daily oral doses \geq 30 mg/m² (approximately 0.5 times the 291 AUC in cancer patients at the recommended human dose). Dogs showed tubular 292 degeneration in the testes at 600 mg/m²/day (approximately 0.3 times the AUC at the recommended human dose) and oligospermia at 1200 mg/m²/day of sorafenib. 293

Adequate contraception should be used during therapy and for at least 2 weeks after completing therapy.

296 **Pregnancy Category D (see WARNINGS)**

297 Nursing Mothers

It is not known whether sorafenib is excreted in human milk. Following administration of ¹⁴C-sorafenib to lactating Wistar rats, approximately 27% of the radioactivity was secreted into the milk. The milk to plasma AUC ratio was approximately 5:1.

Because many drugs are excreted in human milk and because the effects of sorafenib on infants have not been studied, women should be advised against breast-feeding while receiving NEXAVAR.

304 **Pediatric Use**

305 The safety and effectiveness of NEXAVAR in pediatric patients have not been studied.

306 Repeat dosing of sorafenib to young and growing dogs resulted in irregular thickening of the

- femoral growth plate at daily sorafenib doses $\geq 600 \text{ mg/m}^2$ (approximately 0.3 times the AUC
- 308 at the recommended human dose), hypocellularity of the bone marrow adjoining the growth 309 plate at 200 mg/m²/day (approximately 0.1 times the AUC at the recommended human dose),
- and alterations of the dentin composition at $600 \text{ mg/m}^2/\text{day}$. Similar effects were not
- 311 observed in adult dogs when dosed for 4 weeks or less.

312 Geriatric Use

313 In total, 32% of RCC patients treated with NEXAVAR were age 65 years or older, and 4%

- were 75 and older. No differences in safety or efficacy were observed between older and
- 315 younger patients, and other reported clinical experience has not identified differences in

316 responses between the elderly and younger patients, but greater sensitivity of some older

317 individuals cannot be ruled out.

318 Information for Patients (see Patient Information About: NEXAVAR)

319 Physicians should inform female patients that NEXAVAR may cause birth defects or fetal

320 loss and that they should not become pregnant during treatment with NEXAVAR and for at

321 least 2 weeks after stopping treatment. Both male and female patients should be counseled to

- 322 use effective birth control during treatment with NEXAVAR and for at least 2 weeks after
- stopping treatment. Female patients should also be advised against breast-feeding whilereceiving NEXAVAR.
- 325

326 Patients should be advised of the possible occurrence of hand-foot skin reaction and rash

- 327 during NEXAVAR treatment and appropriate countermeasures. Patients should be informed
- 328 that hypertension may develop during NEXAVAR treatment, especially during the first six
- 329 weeks of therapy, and that blood pressure should be monitored regularly during treatment.
- 330
- Physicians should inform patients that NEXAVAR may increase the risk of bleeding and thatthey should promptly report any episodes of bleeding.
- 333

334 Physicians should also discuss with patients that cardiac ischemia and/or infarction has been

- reported during NEXAVAR treatment, and that they should immediately report any episodes
- 336 of chest pain or other symptoms of cardiac ischemia and/or infarction.
- 337

338 ADVERSE REACTIONS

339 Safety evaluation of NEXAVAR is based on 1286 cancer patients who received NEXAVAR

340 as monotherapy and 165 patients who received NEXAVAR concurrently with chemotherapy.

341 A total of 346 patients were exposed to NEXAVAR monotherapy for greater than 6 months.

- 342 A total of 664 RCC patients received NEXAVAR monotherapy, of whom 215 were treated
- 343 for at least 6 months.

Table 2 shows the percent of patients experiencing treatment-emergent adverse events that were reported in at least 10% of patients who received NEXAVAR in Study 1. CTCAE Grade 3 treatment-emergent adverse events were reported in 31% of patients receiving NEXAVAR compared to 22% of patients receiving placebo. CTCAE Grade 4 treatmentemergent adverse events were reported in 7% of patients receiving NEXAVAR compared to 6% of patients receiving placebo.

Table 2: Treatment-Emergent Adverse Events Reported in at Least 10% of NEXAVAR-Treated Patients – Study 1

	NEXAVAR N=451			Placebo N=451		
Adverse Event NCI- CTCAE v3 Category/Term	All Grades %	Grade 3 %	Grade 4 %	All Grades %	Grade 3 %	Grade 4 %
Any Event	95	31	7	86	22	6
Cardiovascular, General				_		
Hypertension	17	3	<1	2	<1	0
Constitutional symptoms						
Fatigue	37	5	<1	28	3	<1
Weight loss	10	<1	0	6	0	0
Dermatology/skin						
Rash/desquamation	40	<1	0	16	<1	0
Hand -foot skin reaction	30	6	0	7	0	0
Alopecia	27	<1	0	3	0	0
Pruritus	19	<1	0	6	0	0
Dry skin	11	0	0	4	0	0
Gastrointestinal						
symptoms						
Diarrhea	43	2	0	13	<1	0
Nausea	23	<1	0	19	<1	0
Anorexia	16	<1	0	13	1	0
Vomiting	16	<1	Õ	12	1	Õ
Constipation	15	<1	0	11	<1	0
Hemorrhage/bleeding						
Hemorrhage – all sites	15	2	0	8	1	<1
Neurology						
Neuropathy-sensory	13	<1	0	6	<1	0
Pain						
Pain, abdomen	11	2	0	9	2	0
Pain, joint	10	2	Õ	6	<1	Õ
Pain, headache	10	<1	0	6	<1	0
Pulmonary						
Dyspnea	14	3	<1	12	2	<1
Cough	13	<1	0	14	_ <1	0

352 The rate of adverse events (including events associated with progressive disease) resulting in

353 permanent discontinuation was similar in both the NEXAVAR and placebo groups (10% of

354 NEXAVAR patients and 8% of placebo patients).

355 Safety was also assessed in a Phase 2 study pool comprised of 638 NEXAVAR-treated 356 patients, including 202 patients with RCC, 137 patients with hepatocellular carcinoma, and 357 299 patients with other cancers. The most common drug-related adverse events reported in

- 358 NEXAVAR-treated patients in this pool were rash (38%), diarrhea (37%), hand-foot skin
- reaction (35%), and fatigue (33%). The respective rates of CTC (v 2.0) Grade 3 and 4 drug-
- 360 related adverse events in NEXAVAR-treated patients were 37% and 3%, respectively.

361 Additional Data from Multiple Clinical Trials

- 362 The following additional drug-related adverse events and laboratory abnormalities were
- 363 reported from clinical trials of NEXAVAR in 1286 cancer patients who received NEXAVAR
- as monotherapy (*very common* 10% or greater, *common* 1 to less than 10%, *uncommon* 0.1%
 to less than 1%):
- 366 **Cardiovascular:** *Uncommon:* hypertensive crisis, myocardial ischemia and/or infarction
- 367 Dermatologic: Very common: erythema Common: exfoliative dermatitis, acne, flushing
 368 Uncommon: folliculitis, eczema, erythema multiforme
- 369 **Digestive:** *Very common:* increased lipase, increased amylase *Common:* mucositis, stomatitis
- 370 (including dry mouth and glossodynia), dyspepsia, dysphagia Uncommon: pancreatitis,
- 371 gastrointestinal reflux, gastritis
- Note that elevations in lipase are very common (41%, see below); a diagnosis of pancreatitis
 should not be made solely on the basis of abnormal laboratory values
- 374 General Disorders: Very common: asthenia, pain (including mouth pain, bone pain, and
- muscle pain) *Common:* decreased appetite, influenza-like illness, pyrexia *Uncommon:*infection
- 377 Hematologic: Very common: leukopenia, lymphopenia Common: anemia, neutropenia,
 378 thrombocytopenia Uncommon: INR abnormal
- 379 Hypersensitivity: Uncommon: hypersensitivity reactions (including skin reactions and urticaria)
- 381 **Metabolic and Nutritional:** *Very common:* hypophosphatemia *Common:* transient increases
- 382 in transaminases *Uncommon:* dehydration, hyponatremia, transient increases in alkaline
- 383 phosphatase, increased bilirubin (including jaundice), hypothyroidism
- 384 Musculoskeletal: Common: arthralgia, myalgia
- 385 Nervous System and Psychiatric: Common: depression Uncommon: tinnitus
- 386 **Reproductive:** *Common:* erectile dysfunction *Uncommon:* gynecomastia
- 387 **Respiratory:** *Common:* hoarseness *Uncommon:* rhinorrhea
- 388 In addition, the following medically significant adverse events were reported infrequently
- 389 during clinical trials of NEXAVAR: cerebral hemorrhage, transient ischemic attack, cardiac
- 390 failure, arrhythmia, thromboembolism, acute renal failure. For these events, the causal
- 391 relationship to NEXAVAR has not been established.

392 LABORATORY ABNORMALITIES

393 The following laboratory abnormalities were observed in Study 1:

- Hypophosphatemia was a common laboratory finding, observed in 45% of NEXAVARtreated patients compared to 11% of placebo patients. CTCAE Grade 3 hypophosphatemia (1-2 mg/dL) occurred in 13% of NEXAVAR-treated patients and 3% of patients in the placebo group. There were no cases of CTCAE Grade 4 hypophosphatemia (<1 mg/dL) reported in either NEXAVAR or placebo patients. The etiology of hypophosphatemia associated with NEXAVAR is not known.
- 400 Elevated lipase was observed in 41% of patients treated with NEXAVAR compared to 30% 401 of patients in the placebo group. CTCAE Grade 3 or 4 lipase elevations occurred in 12% of 402 patients in the NEXAVAR group compared to 7% of patients in the placebo group. Elevated 403 amylase was observed in 30% of patients treated with NEXAVAR compared to 23% of patients in the placebo group. CTCAE Grade 3 or 4 amylase elevations were reported in 1% 404 405 of patients in the NEXAVAR group compared to 3% of patients in the placebo group. Many 406 of the lipase and amylase elevations were transient, and in the majority of cases NEXAVAR 407 treatment was not interrupted. Clinical pancreatitis was reported in 3 of 451 NEXAVAR-408 treated patients (one CTCAE Grade 2 and two Grade 4) and 1 of 451 patients (CTCAE Grade 409 2) in the placebo group.
- 410 Lymphopenia was observed in 23% of NEXAVAR-treated patients and 13% of placebo
- 411 patients. CTCAE Grade 3 or 4 lymphopenia was reported in 13% of NEXAVAR-treated
- 412 patients and 7% of placebo patients. Neutropenia was observed in 18% of NEXAVAR-
- 413 treated patients and 10% of placebo patients. CTCAE Grade 3 or 4 neutropenia was reported
- 414 in 5% of NEXAVAR-treated patients and 2% of placebo patients.
- 415 Anemia was observed in 44% of NEXAVAR-treated patients and 49% of placebo patients.
- 416 CTCAE Grade 3 or 4 anemia was reported in 2% of NEXAVAR-treated patients and 4% of
- 417 placebo patients.
- 418 Thrombocytopenia was observed in 12% of NEXAVAR-treated patients and 5% of placebo
- 419 patients. CTCAE Grade 3 or 4 thrombocytopenia was reported in 1% of NEXAVAR-treated
- 420 patients and 0% of placebo patients.

421 **OVERDOSAGE**

- 422 There is no specific treatment for NEXAVAR overdose.
- 423 The highest dose of NEXAVAR studied clinically is 800 mg twice daily. The adverse
- 424 reactions observed at this dose were primarily diarrhea and dermatologic events. No
- 425 information is available on symptoms of acute overdose in animals because of the saturation
- 426 of absorption in oral acute toxicity studies conducted in animals.
- 427 In cases of suspected overdose, NEXAVAR should be withheld and supportive care428 instituted.

429 **DOSAGE AND ADMINISTRATION**

- 430 The recommended daily dose of NEXAVAR is 400 mg (2 x 200 mg tablets) taken twice
- 431 daily, without food (at least 1 hour before or 2 hours after eating). Treatment should continue

- 432 until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity
- 433 occurs.
- 434 Management of suspected adverse drug reactions may require temporary interruption and/or
- 435 dose reduction of NEXAVAR therapy. When dose reduction is necessary, the NEXAVAR
- 436 dose may be reduced to 400 mg once daily. If additional dose reduction is required,
- 437 NEXAVAR may be reduced to a single 400 mg dose every other day (see **PRECAUTIONS**).
- 438 Suggested dose modifications for skin toxicity are outlined in Table 3.

439 **Table 3: Suggested Dose Modifications for Skin Toxicity**

Skin Toxicity Grade	Occurrence	Suggested Dose Modification
Grade 1: Numbness, dysesthesia, paresthesia, tingling, painless swelling, erythema or discomfort of the hands or feet which does not disrupt the patient's normal activities	Any occurrence	Continue treatment with NEXAVAR and consider topical therapy for symptomatic relief
Grade 2: Painful erythema and swelling of the hands or feet and/or discomfort affecting the patient's normal activities	1 st occurrence	Continue treatment with NEXAVAR and consider topical therapy for symptomatic relief If no improvement within 7 days, see below
	No improvement within 7 days or 2 nd or 3 rd occurrence	Interrupt NEXAVAR treatment until toxicity resolves to Grade 0-1
		When resuming treatment, decrease NEXAVAR dose by one dose level (400 mg daily or 400 mg every other day)
	4 th occurrence	Discontinue NEXAVAR treatment
Grade 3: Moist desquamation, ulceration, blistering or severe pain of the hands or feet, or severe	1 st or 2 nd occurrence	Interrupt NEXAVAR treatment until toxicity resolves to Grade 0-1
discomfort that causes the patient to be unable to work or perform activities of daily living		When resuming treatment, decrease NEXAVAR dose by one dose level (400 mg daily or 400 mg every other day)
	3 rd occurrence	Discontinue NEXAVAR treatment

441

- 442 No dose adjustment is required on the basis of patient age, gender, body weight, or in patients
- 443 with Child-Pugh A or B hepatic impairment. NEXAVAR has not been studied in patients
- 444 with Child-Pugh C hepatic impairment or severe renal impairment including dialysis patients
- 445 (see CLINICAL PHARMACOLOGY Special Populations Hepatic Impairment,
- 446 **Renal Impairment, and PRECAUTIONS** sections).

447 HOW SUPPLIED

- 448 NEXAVAR tablets are supplied as round, biconvex, red film-coated tablets, debossed with 449 the "Bayer cross" on one side and "200" on the other side, each containing sorafenib tosylate
- 450 equivalent to 200 mg of sorafenib.
- 451 Bottles of 120 tablets NDC 0026-8488-58

452 Storage

453 Store at 25°C (77°F); excursions permitted to 15-30°C (59–86°F) (see USP controlled room 454 temperature). Store in a dry place.

455 **REFERENCES**

- 456 1. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors
- 457 for survival in previously treated patients with metastatic renal cell carcinoma. *J Clin* 458 *Oncol* 2004;223:454-63.

459 **Rx Only**



Manufactured by: Bayer HealthCare

Bayer HealthCare AG, Leverkusen, Germany

Manufactured for:

Bayer Pharmaceuticals Corporation, 400 Morgan Lane, West Haven, CT 06516

Onyx Pharmaceuticals, Inc., 2100 Powell Street, Emeryville, CA 94608

Distributed and marketed by: Bayer Pharmaceuticals Corporation, 400 Morgan Lane, West Haven, CT 06516

Marketed by:



Onyx Pharmaceuticals, Inc., 2100 Powell Street, Emeryville, CA 94608

460

461 Revision number

462 200 Bayer Pharmaceuticals Corporation

12/05 12875 Printed in U.S.A.

463	Patient Information About:
464	NEXAVAR® (NEX-A-VAR)
465	(sorafenib) tobleta 200 mg
466	tablets 200 mg
467 468 469 470	Read the Patient Information that comes with NEXAVAR before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor or healthcare professional about your medical condition or your treatment.
471	What is the most important information I should know about NEXAVAR?
472	NEXAVAR may cause birth defects or death of an unborn baby.
473 474	• Women should not get pregnant during treatment with NEXAVAR and for at least 2 weeks after stopping treatment.
475 476	• Men and women should use effective birth control during treatment with NEXAVAR and for at least 2 weeks after stopping treatment.
477	Call your doctor right away if you become pregnant during treatment with NEXAVAR.
478	What is NEXAVAR?
479 480	NEXAVAR is an anticancer medicine to treat adults with kidney cancer called advanced renal cell carcinoma.
481	NEXAVAR has not been studied in children.
482	Who should not take NEXAVAR?
483 484	• Do not take NEXAVAR if you are allergic to anything in it. See the end of this leaflet for a complete list of ingredients.
485	What should I tell my doctor before starting NEXAVAR?
486	Tell your doctor about all of your health conditions, including if you:
487	• have kidney problems in addition to kidney cancer
488	have liver problems
489	have high blood pressure
490	have bleeding problems
491	• have heart problems or chest pain

- 492 are pregnant. See "What is the most important information I should know about NEXAVAR?"
- **are breast-feeding.** NEXAVAR may harm your baby.

495 Tell your doctor about all the medicines you take including prescription and non-

496 prescription medicines, vitamins and herbal supplements. NEXAVAR and certain 497 other medicines can interact with each other and cause serious side effects. Especially,

498 tell vour doctor if vou take warfarin (Coumadin®)*.

- 499 Know the medicines you take. Keep a list of them to show to your doctor and
- 500 pharmacist. Do not take other medicines with NEXAVAR until you have talked with 501 your doctor.
- If you need to have a surgical or dental procedure, tell your doctor that you are takingNEXAVAR.

504 How do I take NEXAVAR?

- Take NEXAVAR exactly as prescribed. You will stay on NEXAVAR as long as
 your doctor thinks it is helping you.
- The usual dose of NEXAVAR is 2 tablets taken twice a day (for a total of 4 tablets per day). Your doctor may adjust your dose during treatment or stop treatment for some time if you have side effects.
- 510 Swallow NEXAVAR tablets whole with water.
- Take NEXAVAR on an empty stomach (at least 1 hour before or 2 hours after a meal).
- If you miss a dose of NEXAVAR, skip the missed dose, and take your next dose at
 your regular time. Do **not** double your dose of NEXAVAR. Call your doctor right
 away if you take too much NEXAVAR.

516 What are possible side effects of NEXAVAR?

- 517 NEXAVAR may cause serious side effects, including:
- birth defects or death of an unborn baby. See "What is the most important information I should know about NEXAVAR?"
- a skin problem called hand-foot skin reaction. This causes redness, pain, swelling,
 or blisters on the palms of your hands or soles of your feet. If you get this side effect,
 your doctor may adjust your dose or stop treatment for some time.

- high blood pressure. Your blood pressure should be checked weekly during the first
 6 weeks of starting NEXAVAR. High blood pressure should be monitored and
 treated during treatment with NEXAVAR.
- heart problems. Talk to your doctor about these potential problems.
- 527
- **bleeding problems.** NEXAVAR may increase your chance of bleeding.
- 529 Other side effects with NEXAVAR may include:
- rash, redness or itching of your skin
- hair thinning or patchy hair loss
- diarrhea (frequent and/or loose bowel movements)
- nausea and/or vomiting
- mouth sores
- weakness
- loss of appetite
- numbness, tingling or pain in your hands and feet
- 538 Talk with your doctor about ways to manage any side effects.

These are not all the side effects with NEXAVAR. Ask your doctor or pharmacist formore information.

541 How should I store NEXAVAR?

- Store NEXAVAR tablets at room temperature between 59° 86° F (15° to 30° C), in a dry place.
- Keep NEXAVAR and all medicines out of the reach of children.

545 General information about NEXAVAR

- 546 Medicines are sometimes prescribed for purposes other than those listed in the patient
- 547 information leaflet. Do not use NEXAVAR for a condition for which it is not prescribed.
- 548 Do not share your medicine with other people even if they have the same symptoms you 549 have. It may harm them.
- 550 This leaflet summarizes the most important information about NEXAVAR. If you would
- 551 like more information, talk with your doctor. You can ask your doctor or pharmacist for
- 552 information about NEXAVAR that is written for healthcare professionals.

553 Website and toll free number:

554 <u>www.nexavar.com</u>

555 1-866-NEXAVAR (1-866-639-2827)

- 556
- 557 What are the ingredients in NEXAVAR?
- 558 Active Ingredient: sorafenib tosylate
- Inactive Ingredients: croscarmellose sodium, microcrystalline cellulose, hypromellose, 559
- sodium lauryl sulphate, magnesium stearate, polyethylene glycol, titanium dioxide and 560 561 ferric oxide red.
- 562 **Rx Only**
- 563 *Coumadin (warfarin sodium) is a trademark of Bristol-Myers Squibb Company



Leverkusen, Germany

Manufactured for:

Bayer Pharmaceuticals Corporation, 400 Morgan Lane, West Haven, CT 06516 Onyx Pharmaceuticals, Inc., 2100 Powell Street, Emeryville, CA 94608

Distributed and marketed by: Bayer Pharmaceuticals Corporation, 400 Morgan Lane, West Haven, CT 06516

Marketed by:



n Pharmaceuticals Onyx Pharmaceuticals, Inc., 2100 Powell Street, Emeryville, CA 94608

- 564
- 565 **Revision number**
- 200 Bayer Pharmaceuticals Corporation 566

12/0512875 Printed in U.S.A.

